Radovich Peter 4

What Happened

• Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals, exercised stock options on 2026-03-06 to acquire 5,912 shares at an exercise price of $15.87 per share, costing $93,823 in total. The filing also reports the related derivative instrument (the option) being converted/disposed (5,912 units, $0), which reflects the option-to-share conversion. This is an acquisition of shares (not a sale).

Key Details

• Transaction date: 2026-03-06
• Acquisition: 5,912 shares @ $15.87 = $93,823
• Derivative disposition: 5,912 units @ $0 (represents conversion of the exercised option)
• Shares owned after transaction: Not specified in the provided filing details
• Footnote: F1 — the stock option was fully vested at exercise
• Filing date: Form 4 filed 2026-03-11 (five days after the transaction). Form 4s are typically due within two business days, so the filing appears later than the usual reporting window.

Context

• This was an option exercise (transaction code M). The filing shows the option converted into shares rather than an immediate sale of acquired shares (no sale reported), so the insider ended up holding the shares after exercise. Exercises of vested options are common for executives and can simply reflect option maturity or personal tax/cashflow planning rather than a market view; they are informative but not definitive evidence of sentiment.